P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS

P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS

Bibliographic Details
Main Authors:	F. Lansigan, D. J. Andorsky, M. Coleman, A. Yacoub, J. M. Melear, S. R. Fanning, K. S. Kolibaba, C. Reynolds, G. S. Nowakowski, M. Gharibo, J. R. Ahn, J. Li, M. J. Rummel, J. P. Sharman
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847492.88194.df

Similar Items

INTERIM ANALYSIS OF MAGNIFY PHASE IIIB: INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL)
by: D.J. Andorsky, et al.
Published: (2020-11-01)

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma
by: Nathan H. Fowler, et al.
Published: (2015-11-01)

Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
by: Giulio Cassanello, et al.
Published: (2024-09-01)

Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
by: James L. Rubenstein, et al.
Published: (2018-07-01)

P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL
by: P. L. Zinzani, et al.
Published: (2022-06-01)

A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
by: Chaitra Ujjani, et al.
Published: (2018-04-01)

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
by: Robert Chen, et al.
Published: (2015-03-01)

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi
by: Stefano Sacchi, et al.
Published: (2016-05-01)

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL
by: P. L. Zinzani, et al.
Published: (2022-06-01)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
by: L. H. Sehn, et al.
Published: (2022-06-01)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
by: Marco Gunnellini, et al.
Published: (2012-01-01)

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
by: Changhee Park, et al.
Published: (2024-03-01)

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
by: Sven de Vos, et al.
Published: (2016-12-01)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
by: L. Nastoupil, et al.
Published: (2022-06-01)

Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trialResearch in context
by: Ashwath Gurumurthi, et al.
Published: (2024-08-01)

P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY
by: N. L. Bartlett, et al.
Published: (2022-06-01)

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
by: Francesco Zaja, et al.
Published: (2017-05-01)

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma
by: Todd A. Fehniger, et al.
Published: (2023-09-01)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
by: Umberto Vitolo, et al.
Published: (2023-08-01)

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trialResearch in context
by: Jonathan W. Friedberg, et al.
Published: (2024-12-01)

Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study
by: Simon Rule, et al.
Published: (2021-06-01)

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
by: Wendy B.C. Stevens, et al.
Published: (2020-02-01)

S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA
by: D. Dytfeld, et al.
Published: (2022-06-01)

BST1047+1156: A (Failing) Ultradiffuse Tidal Dwarf in the Leo I Group
by: J. Christopher Mihos, et al.
Published: (2024-01-01)

P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
by: Paolo Strati, et al.
Published: (2023-08-01)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
by: R. Palmieri, et al.
Published: (2019-01-01)

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma
by: Robin Noel, et al.
Published: (2023-12-01)

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
by: Ajai Chari, et al.
Published: (2017-08-01)

Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas
by: Roopesh Kansara, et al.
Published: (2016-10-01)

An estimation method of the spatial resolution for magnifying fast neutron radiography
by: J. J. Li, et al.
Published: (2022-05-01)

Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial
by: Vaishali Sanchorawala, et al.
Published: (2013-05-01)

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
by: Antonio Salar Silvestre, et al.
Published: (2023-08-01)

Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
by: Xianggui Yuan, et al.
Published: (2024-02-01)

Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia
by: Candida Vitale, et al.
Published: (2019-01-01)

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 studyResearch in context
by: Radhakrishnan Ramchandren, et al.
Published: (2023-02-01)

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
by: D. Belada, et al.
Published: (2022-06-01)

Too much and not enough: revisiting maintenance rituximab in indolent lymphomas
by: Sonali Smith
Published: (2021-06-01)

HISTORY OF TWO COUNCILS HELDAT CONSTANTINOPLE IN 1156–1157 AS DESCRIBED BY D. M. SUDNITSYN
by: PAVEL ERMILOV
Published: (2010-08-01)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
by: J. P. Sharman, et al.
Published: (2022-06-01)

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
by: Ajay Major, et al.
Published: (2021-07-01)